中國(guó)司法機(jī)關(guān)經(jīng)過全面深入調(diào)查，依法認(rèn)定葛蘭素史克中國(guó)公司為謀取不正當(dāng)利益,，給予非國(guó)家工作人員財(cái)物,，構(gòu)成對(duì)非國(guó)家工作人員行賄罪。葛蘭素史克總公司完全認(rèn)同中國(guó)司法機(jī)關(guān)依法認(rèn)定的事實(shí)和證據(jù),，服從中國(guó)司法機(jī)關(guān)的依法判決,，并向中國(guó)患者、醫(yī)生,、醫(yī)院和中國(guó)政府,、全體中國(guó)人民深刻道歉，對(duì)于由此造成的損害,，葛蘭素史克總公司深感痛心和愧疚,。對(duì)由于受到葛蘭素史克中國(guó)公司非法調(diào)查而受到傷害的有關(guān)人員，葛蘭素史克總公司也深表歉意,。
葛蘭素史克中國(guó)公司的違法行為同樣嚴(yán)重違背了葛蘭素史克總公司的規(guī)章制度,，完全背離了總公司要求員工遵守的價(jià)值觀和行為準(zhǔn)則。這些行為未能及時(shí)被發(fā)現(xiàn)并被制止,，葛蘭素史克總公司深感遺憾,。葛蘭素史克總公司已經(jīng)深刻反省，并從中吸取教訓(xùn),，采取了具體措施,，全面整改葛蘭素史克中國(guó)公司運(yùn)營(yíng)中存在的問題，盡一切努力,，重新贏得中國(guó)人民的信任,。
今天，葛蘭素史克總公司進(jìn)一步向中國(guó)政府和人民承諾,，葛蘭素史克中國(guó)公司將以實(shí)際行動(dòng)在中國(guó)醫(yī)藥行業(yè)樹立改革的樣板：將堅(jiān)持在中國(guó)持續(xù)投資,，并一如既往地支持中國(guó)的科技發(fā)展；將針對(duì)流行于中國(guó)的疾病,，進(jìn)一步推進(jìn)藥物和疫苗的研發(fā),。葛蘭素史克中國(guó)公司還將通過擴(kuò)大生產(chǎn),、擴(kuò)大藥品價(jià)格下浮空間，讓中國(guó)農(nóng)村地區(qū)和城市一樣,，提高對(duì)葛蘭素史克藥品的可及性,。
葛蘭素史克總公司將以踐行這一系列長(zhǎng)遠(yuǎn)的發(fā)展戰(zhàn)略，致力于促進(jìn)中國(guó)人民的健康福祉,，為中國(guó)經(jīng)濟(jì)社會(huì)發(fā)展積極貢獻(xiàn)力量,。
GSK plc Statement of Apology to the People of China
Following a comprehensive investigation by the Chinese judicial authorities， GSK China Investment Co. Ltd (GSKCI) has been identified according to Chinese law to have offered money or property to non-government personnel in order to obtain improper commercial gains,， and has been found guilty of bribing non-government personnel. GSK plc fully accepts the facts and evidence of the investigation,， and the verdict of the Chinese judicial authorities. Furthermore， GSK plc sincerely apologises to the Chinese patients,， doctors and hospitals,， and to the Chinese Government and the Chinese people. GSK plc deeply regrets the damage caused. GSK plc also apologises for the harm caused to individuals who were illegally investigated by GSKCI.
The illegal activities of GSKCI are a clear breach of GSK plc’s governance and compliance procedures; and are wholly contrary to the values and standards we expect from our employees. It is deeply disappointing that these issues were not identified and addressed. GSK plc has reflected deeply and learned from its mistakes， has taken steps to comprehensively rectify the issues identified at the operations of GSKCI,， and must work hard to regain the trust of the Chinese people.
Today,， GSK plc makes a further commitment to the Chinese government and people that GSKCI will take tangible actions to establish itself as a model for reform in China’s healthcare industry： by continuing to invest in China and supporting China's scientific development; and by further development of innovative new medicines and vaccines for diseases prevalent in China. GSKCI will also increase access to its products in both city and rural areas of China through greater expansion of production and through price flexibility.
